AMRN Chugs Along, ATHX To Initiate Pivotal COVID-19 Trial, WORX Soars 550%

Today’s Daily Dose brings you news about Amarin’s preliminary Q1 revenue; Athersys’ initiation of a phase II/III pivotal study of MultiStem therapy in COVID-19-induced acute respiratory distress syndrome; Fennec Pharma’s regulatory catalyst in August; initial data of Gilead’s Remdesivir in … Read more…